Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy

This publication has 20 references indexed in Scilit:

• Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
  AIDS, 2000
• Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients
  Antimicrobial Agents and Chemotherapy, 2000
• Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
  AIDS, 2000
• Recurrent NNRTI-Induced Hepatotoxicity in an HIV-HCV-Coinfected Patient
  Annals of Pharmacotherapy, 2000
• Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
  JAMA, 2000
• Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
  AIDS, 1999
• Efavirenz: shifting the HAART paradigm in adult HIV-1 infection
  Expert Opinion on Investigational Drugs, 1999
• Hepatotoxicity after introduction of highly active antiretroviral therapy
  AIDS, 1998
• Severe hepatitis in three AIDS patients treated with indinavir
  The Lancet, 1997
• Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use
  Expert Opinion on Investigational Drugs, 1996